Skip to Main Content

Gunning to beat back a global scourge of superbugs, a transatlantic group is committing tens of millions of dollars, some of that from American taxpayers, to back biotech startups developing novel antibiotics.

The project, called CARB-X, plans to dole out $44 million in its first year and as much as $350 million in the next five years in grants to small companies. It’ll draw funds from the US government and a public-private initiative in the United Kingdom.


The goal is to get at least two new drugs into human trials in the next five years.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!